Hering W, Ihmsen H, Uhrlau C, Schüttler J
Klinik für Anästhesiologie, Friedrich-Alexander-Universität Erlangen-Nürnberg.
Anaesthesist. 1996 Dec;45(12):1142-50. doi: 10.1007/s001010050350.
During the last five years several authors have reported largely satisfactory results, using the steroid intravenous anaesthetic eltanolone (pregnanolone) for induction of anaesthesia after administering a bolus dose. Until now, however, no investigations have been undertaken, dealing with the infusion pharmacokinetics of eltanolone after arterial blood sampling and using slow induction to quantify the concentration-effect relationship. Secondary objectives were to assess the haemodynamic and respiratory effects.
Eltanolone emulsion was administered to 12 healthy male volunteers using a computer-controlled infusion device. Linearly increasing serum concentrations were generated for two consecutive times with an anticipated slope of 0.075 microgram ml-1 min-1 and with a targeted concentration of 2 micrograms ml-1. During and following the infusion, EEG was recorded and clinical signs were assessed as measure of the hypnotic effect. Thus, the time intervals from start of infusion until the volunteers fell asleep, until they did no longer respond to loud verbal commands, until loss of the corneal reflex and until the appearance of burst suppression patterns in the EEG were recorded. The latter sign was used as endpoint for the infusion. After the cessation of the infusion the time intervals until the disappearance of burst suppression and the reappearance of the clinical signs were recorded until full orientation was regained. Arterial blood samples were frequently drawn up to 720 min following the cessation of the last infusion cycle. Eltanolone serum concentrations were measured by a specific GC-MS assay. Pharmacokinetics were analysed with NONMEM by an open three compartment model. The serum concentrations were correlated with the corresponding clinical signs to quantify the concentration-effect relationship. Blood pressure, heart rate and oxygen saturation were measured continuously and the arterial pCO2 was analysed every 6 min.
The model-dependent pharmacokinetic parameters of eltanolone were characterized by a high total clearance (1.75 +/- 0.22 l min-1), small volumes of distribution (Vc = 7.7 +/- 3.4 l; Vdss = 92 +/- 22 l and relatively short half-lives (t1/2 alpha = 1.5 +/- 0.6 min; t1/2 beta = 27 +/- 5 min; t1/2 gamma = 184 +/- 32 min). (Table 2). The clinical signs revealed a good hypnotic effect, resulting in burst suppression periods in the EEG after 19 min during the first and 15 min during the second infusion cycle. The slow induction enabled a thorough observation of the induction phase. During the first infusion cycle cessation of counting occurred after 7.7 +/- 1.3 min (mean +/- SD), reaction to verbal contact was lost after 10.4 +/- 1.3 min and the corneal reflex was lost only in about one half of the volunteers after 17.9 +/- 2.8. During recovery, the corneal reflex reappeared 9.4 +/- 2.4 min after stop of infusion, first reactions to loud verbal commands were recorded after 24.2 +/- 4.3 min and full orientation was regained after 34.7 +/- 6.2 min. During the second cycle all signs disappeared faster and were regained later. The correlation between clinical signs and corresponding serum concentrations revealed, that in both cycles the disappearance occurred at clearly higher concentrations than the reappearance. The decrease of the systolic arterial pressure showed a maximum of 31% compared to the baseline values, which was statistically significant (P < 0.05). Diastolic arterial blood pressure decreased of about 10%, while heart rate increased significantly of about 24% (P < 0.05). Oxygen saturation remained stable with values between 96 and 100% with the exception of one volunteer. Apnoea was not recorded during the entire observation period. The median value of all pCO2 analyses was 41 mmHg with a range of 25-60 mmHg. The only serious undesirable effect was a seizure during awakening in one volunteer which coincided with polyspike waves in his raw-EEG recordings. (ABSTRACT TR
在过去五年中,几位作者报告了使用类固醇静脉麻醉药艾坦诺龙(孕烷醇酮)静脉推注诱导麻醉取得了总体令人满意的结果。然而,迄今为止,尚未进行过关于动脉采血后艾坦诺龙输注药代动力学以及使用缓慢诱导来量化浓度 - 效应关系的研究。次要目标是评估血流动力学和呼吸效应。
使用计算机控制输注装置,将艾坦诺龙乳剂给予12名健康男性志愿者。连续两次生成线性增加的血清浓度,预期斜率为0.075微克·毫升⁻¹·分钟⁻¹,目标浓度为2微克·毫升⁻¹。在输注期间及之后,记录脑电图(EEG)并评估临床体征作为催眠效果的指标。因此,记录从输注开始到志愿者入睡、直到他们不再对大声言语指令有反应、直到角膜反射消失以及直到脑电图中出现爆发抑制模式的时间间隔。后者被用作输注的终点。输注停止后,记录直到爆发抑制消失和临床体征重新出现的时间间隔,直到完全恢复定向。在最后一个输注周期停止后长达720分钟内频繁采集动脉血样。通过特定的气相色谱 - 质谱(GC - MS)测定法测量艾坦诺龙血清浓度。使用非参数混合效应模型(NONMEM)通过开放三室模型分析药代动力学。将血清浓度与相应的临床体征相关联以量化浓度 - 效应关系。连续测量血压、心率和血氧饱和度,每6分钟分析一次动脉血二氧化碳分压(pCO₂)。
艾坦诺龙的模型依赖性药代动力学参数的特征为总清除率高(1.75±0.22升·分钟⁻¹)、分布容积小(中央室容积Vc = 7.7±3.4升;稳态分布容积Vdss = 92±22升)以及半衰期相对较短(α半衰期t1/2α = 1.5±0.6分钟;β半衰期t1/2β = 27±5分钟;γ半衰期t1/2γ = 184±32分钟)。(表2)。临床体征显示出良好催眠效果,在第一个输注周期中19分钟后、第二个输注周期中15分钟后脑电图中出现爆发抑制期。缓慢诱导使得能够全面观察诱导期。在第一个输注周期中,7.7±1.3分钟(平均值±标准差)后停止计数,10.4±1.3分钟后失去对言语接触的反应,17.9±2.8分钟后仅约一半志愿者角膜反射消失。恢复期间,输注停止后9.4±2.4分钟角膜反射重新出现;24.2±4.3分钟后记录到对大声言语指令的首次反应;34.7±6.2分钟后完全恢复定向。在第二个周期中,所有体征消失更快且恢复更晚。临床体征与相应血清浓度之间的相关性显示,在两个周期中,消失时的浓度明显高于重新出现时的浓度。收缩压与基线值相比最大下降31%,具有统计学意义(P < 0.05)。舒张压下降约10%,而心率显著增加约24%(P < 0.05)。除一名志愿者外,血氧饱和度保持稳定,值在96%至100%之间。在整个观察期内未记录到呼吸暂停。所有pCO₂分析的中位数为41 mmHg,范围为25 - 60 mmHg。唯一严重的不良事件是一名志愿者苏醒期间发生癫痫发作,这与他原始脑电图记录中的多棘波一致。(摘要TR)